Pancreatic cancer–associated fibroblasts: Where do we go from here? Review
| Authors: | Carpenter, E. S.; Vendramini-Costa, D. B.; Hasselluhn, M. C.; Maitra, A.; Olive, K. P.; Cukierman, E.; Pasca di Magliano, M.; Sherman, M. H. |
| Review Title: | Pancreatic cancer–associated fibroblasts: Where do we go from here? |
| Abstract: | Pancreatic ductal adenocarcinoma is a deadly disease and is projected to become the second leading cause of cancer-related death by 2030. A major hallmark is the exuberant host response comprising the tumor microenvironment, of which, cancer-associated fibroblasts (CAF) are a prevalent component. Despite the gains in understanding of their heterogeneity and functionality from CAF studies in recent years, there are many unanswered questions surrounding this diverse population of cells. Here, we summarize the views of several experts in the field, focusing on the current understanding of CAFs and challenges to address. © 2024 American Association for Cancer Research. |
| Keywords: | pancreatic neoplasms; animal; metabolism; animals; carcinoma, pancreatic ductal; pathology; drug specificity; cancer mortality; immune response; ischemia time; cell surface marker; pancreas tumor; paracrine signaling; recurrent disease; immunomodulation; immunosuppressive treatment; secretome; mesothelium cell; chronic wound; smooth muscle actin; tumor microenvironment; cancer associated fibroblast; epithelial mesenchymal transition; pancreatic ductal carcinoma; interleukin 33; humans; cancer-associated fibroblasts; human; article; pancreatic cancer–associated fibroblast |
| Journal Title: | Cancer Research |
| Volume: | 84 |
| Issue: | 21 |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2024-11-01 |
| Start Page: | 3505 |
| End Page: | 3508 |
| Language: | English |
| DOI: | 10.1158/0008-5472.Can-24-2860 |
| PUBMED: | 39283867 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
